Vivaldi Capital Management LP

Position in URGN — UroGen Pharma Ltd.

CIK 1682021 CHICAGO, IL

Position in URGN

as of Mar 31, 2026 · filed May 14, 2026 Compact

Position Value

$281,584

-$85,196 QoQ

Shares Held

15,661

0.0% QoQ

Ownership

0.032%

of shares outstanding

% of Portfolio

0.06%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2020

15 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

Vivaldi Capital Management LP holds $3,172,478 across 4 Biotechnology names. URGN ranks #4 (8.9% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	HALO	Halozyme Therapeutics, Inc.	24,499	$1,583,370
2	GALT	Galectin Therapeutics Inc	258,584	$721,449
3	LENZ	LENZ Therapeutics, Inc.	64,052	$586,075
4	URGN	UroGen Pharma Ltd. This page	15,661	$281,584

15 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$281,584	15,661	0.0%	Shares	Sole	2026-05-14
2025-12-31	$366,780	15,661	0.0%	Shares	Sole	2026-02-13
2025-09-30	$312,436	15,661	0.0%	Shares	Sole	2025-11-17
2025-06-30	$214,555	15,661	-22.2%	Shares	Sole	2025-08-14
2025-03-31	$222,571	20,124	0.0%	Shares	Sole	2025-05-15
2024-12-31	$214,320	20,124	0.0%	Shares	Sole	2025-02-14
2024-09-30	$255,574	20,124	0.0%	Shares	Sole	2024-11-14
2024-06-30	$337,680	20,124	0.0%	Shares	Sole	2024-08-14
2024-03-31	$301,860	20,124	+22.3%	Shares	Sole	2024-05-15
2023-12-31	$246,915	16,461	0.0%	Shares	Sole	2024-02-14
2023-09-30	$230,618	16,461	+43.1%	Shares	Sole	2023-11-14
2023-06-30	$119,025	11,500	-30.9%	Shares	Sole	2023-08-14
2021-09-30	$280,053	16,650	+66.5%	Shares	Sole	2021-11-16
2020-09-30	$192,900	10,000	-9.1%	Shares	Sole	2020-11-16
2020-06-30	$287,320	11,000	—	Shares	Sole	2020-08-13
No filing history on record for this holder in this stock.